Predicting prognosis in patients with inflammatory bowel disease

Crohn disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease, affecting approximately 1 million people in the US. The severity of the symptoms and the frequency with which they recur varies widely among patients. Kenneth Smith and colleagues, at the University of Cambridge, United Kingdom, have now identified a gene expression profile that can divide patients with CD and UC into two otherwise undistinguishable subgroups -- those with a high incidence of treatment-nonresponsive, frequently relapsing, or chronically active disease and those with mild disease. As discussed by the authors and, in an accompanying commentary, Laurence Turka, Simon Robson, and David Friedman, these data should allow physicians to identify those patients that require aggressive therapies such as potent immune system-suppressing drugs and prevent those that do not need such drugs from being exposed to their rare but potentially life-threatening side effects.

TITLE: Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

AUTHOR CONTACT:
Kenneth G.C. Smith
University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Phone: 44.1223.336848; Fax: 44.1223.336846; E-mail: [email protected]

View this article at: http://www.jci.org/articles/view/59255?key=e497ac519765f9202fce

ACCOMPANYING COMMENTARY

TITLE: There's a goat behind door number 3: from Monty Hall to medicine

AUTHOR CONTACT:

Laurence A. Turka
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
E-mail: [email protected]

Simon C. Robson
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
E-mail: [email protected]

View this article at: http://www.jci.org/articles/view/60003?key=1ba64f03b4752af0b325

 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.